Surgical Robotics Market

A surgical robot is sold once, yet most of the money arrives after it is installed, in the instruments and accessories discarded after each case. That inversion defines the Surgical Robotics Market, which reached USD 13.03 billion in 2025 on 4.214 million robotic procedures × USD 3,092 of revenue per procedure. Douglas Insights projects USD 33.98 billion by 2035, a 10.06% revenue CAGR built from 11.24% procedure growth and a 1.06% annual drift down in revenue per case. Competition finally reached the US soft-tissue room on 3 December 2025, when Medtronic announced FDA clearance of the Hugo robotic-assisted surgery system for urologic procedures. Robots now account for a growing slice of the trays covered in our surgical instruments coverage; procedure counts and revenue per case are reconciled under the Douglas Insights research methodology.

Why does a da Vinci instrument tray earn more than the console it is attached to?

Instruments and accessories brought Intuitive Surgical USD 6.02 billion in 2025, or 59.80% of its USD 10.06 billion revenue, against USD 2.47 billion from systems. The full-year 2025 results also show services at USD 1.57 billion, so recurring lines made up roughly three-quarters of the leader’s sales. The console is the hook. The EndoWrist-style instruments, drapes and staplers are the meter.

Intuitive reports that instrument and accessory revenue per surgical robotics procedure held flat at about USD 1,810 in 2025, while da Vinci procedures grew about 18% to roughly 3,153,000. Volume, not price, carries the model. Each new console placed in a hospital starts a stream of single-use and limited-life instruments for as long as surgeons keep scheduling cases on it.

Systems are also drifting toward recurring money. Of the 1,721 da Vinci systems placed in 2025, 872 went out under operating leases and 496 of those on usage-based terms, according to the company. A hospital on a usage-based lease pays for the surgical robot partly through each procedure, which pulls system revenue into the same per-case receipt that funds instruments.

Who sells surgical robots against da Vinci, and on what installed base?

Intuitive Surgical holds an estimated 77.24% share of surgical robotics revenue, a figure Douglas Insights calculates from its disclosed USD 10.06 billion against the USD 13.03 billion market. The top three vendors together reach about 86.90%, also a Douglas Insights estimate.

Intuitive’s moat is a da Vinci installed base of 11,106 systems at 31 December 2025, up 12%, plus 995 Ion endoluminal systems, as reported in its 2025 Form 10-K and results. Stryker builds on Mako: its 10-K says more than two million robotic procedures across Mako Total Knee, Total Hip and Partial Knee have been performed, with Mako sold in more than 45 countries. Medtronic’s position rests on Hugo, used in more than 30 countries before the December 2025 US urology clearance. Zimmer Biomet competes with ROSA, adding the ROSA Shoulder clearance on 22 February 2024. Globus Medical, which completed its NuVasive merger on 1 September 2023, sells ExcelsiusGPS for spine and ExcelsiusFlex for knees. Johnson & Johnson MedTech fields Monarch for bronchoscopy and Velys for knees, and filed its Ottava soft-tissue robot for De Novo review, announced on 7 January 2026. Smith+Nephew sells the handheld CORI Surgical System. CMR Surgical won US De Novo authorisation for Versius in cholecystectomy on 15 October 2024. KARL STORZ closed its purchase of Asensus Surgical, maker of Senhance, on 22 August 2024, and MicroPort MedBot logged 100 Toumai orders by 9 October 2025.

Does the da Vinci 5 upgrade cycle lift hospital robot budgets or delay them?

Intuitive placed 870 da Vinci 5 systems in 2025, up from 362 a year earlier, so the fifth-generation surgical robot lifted budgets rather than freezing them. The FDA cleared it on 14 March 2024, with more than 150 enhancements and force feedback that cut tissue force by up to 43% in preclinical work. Hospitals with mature programmes took it first. The da Vinci installed base still grew 12% in the same year.

Which surgical robot type makes the money: multiport, orthopaedic or single-port?

Soft-tissue multiport systems take 74.62% of surgical robotics revenue, worth USD 9.72 billion in 2025, and still hold 67.29% in 2035.

Soft-tissue multiport, at USD 9.72 billion, leads because da Vinci Xi and da Vinci 5 consoles perform the bulk of urology, gynaecology and general surgery cases. Orthopaedic robots earn USD 1.68 billion, a 12.86% share, built on knee and hip arthroplasty with Mako, ROSA, CORI and Velys. Neurosurgical and spine systems contribute USD 569.4 million, held back by a smaller number of screw-placement cases per hospital. Single-port systems bring USD 444.3 million; the da Vinci SP opens narrow-access transoral and urologic work. Endoluminal/bronchoscopy platforms, Ion and Monarch, add USD 426.1 million from lung nodule biopsy. Hair restoration and other niches account for USD 191.5 million, the smallest slice. Single-port is the fastest-growing type at 17.83% a year, because one incision suits outpatient urology and colorectal cases and Intuitive has few rivals there.

What fuels robotic procedure growth beyond urology and gynaecology?

Procedure growth of 11.24% a year powers the surgical robotics forecast, and Douglas Insights splits that volume leg into four quantified contributions that add up to the full 11.24 points.

General surgery conversion adds 5.42 points. Intuitive reports US general surgery procedures grew 18% in 2025, led by cholecystectomy, hernia repair and colorectal resection, while outside the US procedures grew 23%. These cases were laparoscopic a decade ago; each one now converted to a console consumes a full instrument kit. Douglas Insights expects robotic penetration of US hernia repair and colectomy to keep rising through 2030 before saturating in the largest academic centres. Intuitive guides to da Vinci procedure growth of 13% to 15% in 2026, which sits above our ten-year volume leg because conversion slows once the easiest cases move. Outside the US, the 23% growth rate comes from a lower base: only 32% of Intuitive revenue was booked abroad in 2025, so each added console in Europe or Japan carries a bigger share of new cases.

Orthopaedic and spine robots contribute 2.87 points. Mako alone has passed two million procedures, and Zimmer Biomet reported FDA clearance of ROSA Knee with OptimiZe in its February 2026 results, which keeps the replacement cycle moving. Joint replacement volumes climb with older populations, and every robot-guided knee draws on implants matched to that vendor’s platform, so orthopaedic makers fund the robot through implant margins. Stryker now adds Mako Shoulder, with full US launch planned for the first quarter of 2026, and Mako Total Hip revision runs on the new Mako 4 platform. Each new application raises cases per installed orthopaedic robot without a new capital sale, a pattern the installed-base tracker below quantifies at roughly 175 cases per system.

Competitive entry in soft tissue contributes 1.71 points. Hugo’s US clearance on 3 December 2025 covers prostatectomy, nephrectomy and cystectomy, which Medtronic counts at about 230,000 US operations a year. Versius and Toumai add second sources for hospitals that held off on a single-vendor contract, and MicroPort reports nearly 80 Toumai installations across almost 40 countries.

Outpatient migration supplies the last 1.24 points. Ambulatory surgery centres buy compact orthopaedic robots for same-day knees and, increasingly, single-port systems for short-stay urology. Our Surgical Robotics Instrument Consumables Market report tracks the disposable side of the same shift. Together: 5.42 + 2.87 + 1.71 + 1.24 = 11.24 points.

How much does a hospital pay per robotic procedure for instruments, service and the console?

Revenue per surgical robotics procedure averages USD 3,092 in 2025 and drifts to about USD 2,779 by 2035 at minus 1.06% a year.

Instruments and accessories cost a da Vinci hospital about USD 1,810 per case, per Intuitive. Douglas Insights derives a systems receipt of about USD 1.29 million per placement from USD 2.47 billion over 1,916 da Vinci and Ion placements, including lease revenue, and service of about USD 138,000 per installed system per year. Orthopaedic platforms realise nearer USD 2,450 per procedure, because robot revenue is shared with implant pricing. Endoluminal/bronchoscopy runs higher, about USD 3,330 per case, as the installed fleet is young and lightly used.

The price leg falls for two reasons. Hugo, Versius and Toumai tender against da Vinci on capital price, and mix shifts toward orthopaedic and ambulatory cases that carry less revenue per procedure. A 2,000-case-a-year programme spends roughly USD 6.18 million annually on robotic receipts.

Where are surgical robot placements growing fastest, from the US to China’s quota?

North America leads surgical robotics at USD 8.00 billion in 2025, while China grows fastest at 13.64% a year to USD 3.71 billion in 2035.

North America holds 61.37% of value and reaches USD 19.05 billion in 2035 at 9.07% a year; Intuitive alone books 68% of its revenue domestically. Europe follows with USD 2.32 billion in 2025, growing 10.12% as national tenders open to Hugo and Versius. China is worth USD 1.03 billion and outpaces every region because quota approvals and domestic NMPA-cleared platforms such as Toumai bring robots into provincial hospitals. Asia Pacific excluding China contributes USD 1.10 billion, growing 12.18% on Japanese and Korean reimbursement for robotic cases. Latin America adds USD 323.1 million and rises 11.83% a year. Gulf hospital projects make the Middle East and Africa the swing region for surgical robots: USD 250.2 million in 2025, 10.13% base growth that a single tender could lift, with CMR and MicroPort both selling there.

Are ambulatory surgery centres ready to buy orthopaedic and single-port robots?

Ambulatory surgery centres account for 8.62% of surgical robotics revenue in 2025, or USD 1.12 billion, against USD 11.91 billion in hospitals.

Hospitals keep the multiport fleet. Centres buy differently: they want a robot that fits a small room, turns over fast and pays back on knees and hips. Short. Payers favour the site. Douglas Insights puts the ambulatory share at 14.37% by 2035, still a minority because soft-tissue consoles need inpatient back-up. Beds and patient-flow decisions, covered in our Smart Hospital Beds Market study, shape how many cases stay inside the hospital.

Which barriers slow robotic surgery adoption in capital-starved hospitals?

Three barriers remove 2.42 points from unconstrained surgical robotics procedure growth of 13.66%, leaving the 11.24% volume leg.

China procurement removes 1.13 points. The 2023 quota permits 559 new surgical robots into China, covering da Vinci and rival systems, and Intuitive warns that sales under it depend on tenders and approvals. Volume-based procurement also squeezes instrument pricing for imported brands.

Hospital capital budgets remove 0.71 points. A console at about USD 1.29 million per placement competes with imaging and bed spend, and smaller hospitals cannot fill one robot with 300 cases a year. Usage-based leases soften this, but 496 such leases in 2025 still represented a minority of placements.

Surgeon training and operating-room time remove 0.58 points. Credentialing on a new robotic platform takes proctored cases, and a hospital running two vendors doubles training. Lessons from compliant actuators in the Soft Robotics Market have not yet shortened that learning curve.

Which FDA, EU MDR and NMPA rules govern a new surgical robot launch?

US surgical robotics launches run through two FDA routes: 510(k) clearance for da Vinci 5 in March 2024, and De Novo for Versius in October 2024.

A 510(k) works when a predicate exists, which is why Hugo and da Vinci 5 cleared that way. A first-of-kind design uses De Novo; J&J chose it for Ottava, with an investigational device exemption study for hernia repair approved in late 2025. In Europe, surgical robots fall under Regulation (EU) 2017/745 (MDR), whose transition periods were extended by Regulation (EU) 2023/607, published on 20 March 2023. Notified-body capacity, not the rule text, sets the pace. In China, the NMPA approves each platform and the quota governs how many large robots enter hospitals; Intuitive’s 10-K quotes 559 units under the original 2023 quota.

What if robotic procedure volumes run faster or slower than the 2035 base case?

The base case reaches USD 33.98 billion in 2035, the slower case USD 24.96 billion and the faster case USD 43.60 billion for surgical robotics.

Base: 11.24% procedure growth and minus 1.06% price, for 12.23 million procedures in 2035. Slower: 8.42% volume and minus 1.57% price, a 6.72% revenue CAGR, if China tenders stall and hospitals delay da Vinci 5 upgrades. Faster: 13.61% volume and minus 0.68% price, a 12.84% CAGR, if Hugo and Ottava expand the buyer pool without starting a price war. Add one point to procedure growth and 2035 revenue rises by USD 3.18 billion; take one away and it falls by USD 2.93 billion. The 3 December 2025 Hugo clearance is the swing factor between the base and the faster case. Published forecasts span about 8.9% to 16.9% a year; our 10.06% sits in the lower third because revenue per procedure declines.

Douglas Exclusive: the surgical robot installed-base tracker

The tracker counts 18,251 installed surgical robots worldwide at end-2025, by platform, country and specialty, and divides each platform’s procedures by its average installed fleet.

Da Vinci leads with 11,106 systems, followed by an estimated 3,900 orthopaedic robots, 1,150 spine and neurosurgical systems, 995 Ion units, 820 non-Intuitive soft-tissue consoles and 280 hair and niche systems. The headline finding is utilisation. An average da Vinci performs about 300 procedures a year. Orthopaedic robots run about 175, spine systems about 103, Ion about 142 and rival soft-tissue consoles about 118. Across all non-Intuitive platforms the average is 151.7 procedures per system, so a da Vinci works 1.98 times harder. For surgical robotics buyers, that gap matters more than list price: a cheaper console used half as often costs more per case. The tracker refreshes each quarter from company disclosures.

Which methodology reconciles robotic procedure counts with the da Vinci installed base?

Surgical robotics value equals 4.214 million procedures × USD 3,092 = USD 13.03 billion, checked against a revenue-stream build that lands within 1.33%.

Procedures: 3.153 million da Vinci (reported), 128,000 Ion, 684,000 orthopaedic, 118,000 spine and neurosurgical, 97,000 other soft-tissue and 34,000 hair and niche, all estimated beyond da Vinci. Cross-check one: Intuitive revenue of USD 10.06 billion, plus rival placements of 1,480 systems at USD 1.02 million, 1.061 million rival procedures at USD 640 in instruments, and service on 6,150 rival systems at 9.8% of capital, sums to USD 12.86 billion. Cross-check two: USD 6.02 billion over 3.281 million da Vinci and Ion procedures gives USD 1,834 per case, 1.3% above Intuitive’s USD 1,810. The model rests on 16 sourced documents, led by Intuitive’s 10-K and quarterly releases. Douglas Insights counts the market revenue mix at 52.10% instruments and accessories, 30.98% system sales and leases and 16.92% service.

Sources

1. Intuitive Surgical Intuitive fourth quarter and full year 2025 results (2026)
2. SEC EDGAR Intuitive Surgical Form 10-K, fiscal 2025 (2026)
3. SEC EDGAR FDA clearance of da Vinci 5 (Form 8-K exhibit) (2024)
4. Medtronic Medtronic announces FDA clearance of Hugo RAS for urologic procedures (2025)
5. SEC EDGAR Stryker Form 10-K, fiscal 2025 (2026)
6. Johnson & Johnson Johnson & Johnson submits OTTAVA to the FDA (2026)
7. EUR-Lex Regulation (EU) 2023/607 (2023)
8. MicroPort Toumai surgical robot reaches 100 orders (2025)